FLT3 and acute myeloid leukemia: Recent advances in the pathogenesis and biology of FLT3 -mutated AML have opened an opportunity for development and application of selective inhibition of FLT3 pathway.<h4>Recent findings</h4>In the last decade, at least three targeted treatments have been approved by regulatory agencies and several others are currently under investigations.